All In Biotech

Drug Trial Radar · NCT05465174

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Tovorafenib for the Treatment of Newly Diagnosed or Recurrent Craniopharyngioma in Children and Young Adults

Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

57

Planned (sponsor's estimate)

Start

Sep 12, 2022

Primary completion

Mar 1, 2027

Study completion Mar 1, 2028

Sponsor

Lead sponsor
Sabine Mueller, MD, PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Day One Biopharmaceuticals, Inc.
First posted
Jul 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 39 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.

Conditions

  • Craniopharyngioma, Child
  • Craniopharyngioma
  • Recurrent Craniopharyngioma

Interventions

  • TovorafenibDrug

    Given orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival rate (PFS)Time frame: Up to 12 months
  2. Changes in scores on the Physical functioning subscale of the Pediatric Quality of Life Inventory (PedsQL) over timeTime frame: Up to 12 months

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Rady Children's Hospital/University of California, San Diego

    San Diego, California · Recruiting

  • University of California, San Francisco

    San Francisco, California · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Riley Hospital for Children at Indiana University Health

    Indianapolis, Indiana · Recruiting

  • John Hopkins University

    Baltimore, Maryland · Recruiting

  • Dana-Farber/Boston Children's Harvard Medical School

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Children's Minnesota

    Minneapolis, Minnesota · Recruiting

  • St. Louis Children's Hospital Washington University

    St Louis, Missouri · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • John Hunter Children's Hospital

    New Lambton Heights, New South Wales, Australia · Recruiting

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia · Recruiting

  • Children's Cancer Centre, Monash Children's Hospital

    Clayton, VIC 3168, Australia · Recruiting

  • Royal Children's Hospital, Childrens' Cancer Centre

    Parkville, Victoria, Australia · Recruiting

  • Perth Children's Hospital

    Nedlands, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.